Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

ISG15 overexpression compensates the defect of Crimean-Congo hemorrhagic fever virus polymerase bearing a protease-inactive ovarian tumor domain.

Tytuł:
ISG15 overexpression compensates the defect of Crimean-Congo hemorrhagic fever virus polymerase bearing a protease-inactive ovarian tumor domain.
Autorzy:
Devignot S; Institute for Virology, FB10-Veterinary Medicine, Justus-Liebig University, Giessen, Germany.
Kromer T; Faculty of Health, Safety, Society, Furtwangen University, Furtwangen, Germany.
Mirazimi A; Public Health Agency of Sweden, Solna, Sweden.; National Veterinary Institute, Solna, Sweden.; Karolinska Institute, Stockholm, Sweden.
Weber F; Institute for Virology, FB10-Veterinary Medicine, Justus-Liebig University, Giessen, Germany.
Źródło:
PLoS neglected tropical diseases [PLoS Negl Trop Dis] 2020 Sep 15; Vol. 14 (9), pp. e0008610. Date of Electronic Publication: 2020 Sep 15 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: San Francisco, CA : Public Library of Science
MeSH Terms:
Cytokines/*genetics
DNA-Directed RNA Polymerases/*genetics
Hemorrhagic Fever Virus, Crimean-Congo/*genetics
Hemorrhagic Fever Virus, Crimean-Congo/*immunology
Peptide Hydrolases/*genetics
Ubiquitins/*genetics
A549 Cells ; Animals ; Cell Line, Tumor ; Chlorocebus aethiops ; Cytokines/metabolism ; DNA-Directed RNA Polymerases/metabolism ; Hemorrhagic Fever, Crimean/pathology ; Humans ; Interferon Type I/immunology ; Protein Domains/genetics ; Protein Processing, Post-Translational/genetics ; Ubiquitins/metabolism ; Vero Cells
References:
Crit Rev Microbiol. 2018 May;44(3):304-317. (PMID: 28885059)
J Virol. 2015 Jun;89(11):5957-67. (PMID: 25810550)
J Gen Virol. 2013 Feb;94(Pt 2):298-307. (PMID: 23136361)
J Virol. 2010 Jan;84(1):216-26. (PMID: 19864393)
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2222-7. (PMID: 21245344)
J Virol. 2013 Jul;87(14):8205-12. (PMID: 23698297)
Antiviral Res. 2015 Aug;120:57-65. (PMID: 26022198)
PLoS Pathog. 2017 May 18;13(5):e1006372. (PMID: 28542609)
J Virol. 2015 Oct;89(20):10219-29. (PMID: 26223644)
Virology. 2009 Mar 15;385(2):400-8. (PMID: 19155037)
PLoS One. 2014 Apr 10;9(4):e94491. (PMID: 24722666)
EMBO J. 1998 Feb 16;17(4):1087-95. (PMID: 9463386)
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):395-404. (PMID: 19027345)
J Virol. 2004 Apr;78(8):4323-9. (PMID: 15047845)
Genom Data. 2015 Dec 28;7:166-70. (PMID: 26981398)
J Gen Virol. 1987 Mar;68 ( Pt 3):945-8. (PMID: 3029315)
mBio. 2019 Jul 23;10(4):. (PMID: 31337717)
Virus Res. 2017 Apr 15;234:118-134. (PMID: 28137457)
J Virol. 2007 Jul;81(13):7011-21. (PMID: 17442719)
Cell Host Microbe. 2007 Dec 13;2(6):404-16. (PMID: 18078692)
J Virol. 1999 Jan;73(1):251-9. (PMID: 9847328)
Cell Host Microbe. 2013 Mar 13;13(3):336-46. (PMID: 23498958)
Curr Opin Microbiol. 2014 Aug;20:96-102. (PMID: 24930021)
J Gen Virol. 2008 Sep;89(Pt 9):2157-2166. (PMID: 18753225)
Curr Opin Immunol. 2015 Feb;32:48-53. (PMID: 25594890)
J Med Virol. 2006 Feb;78(2):216-22. (PMID: 16372299)
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6. (PMID: 23203888)
Virology. 2015 May;479-480:52-65. (PMID: 25753787)
Viruses. 2016 Apr 21;8(4):106. (PMID: 27110812)
Trends Immunol. 2017 Jan;38(1):39-52. (PMID: 27863906)
J Gen Virol. 2009 Jan;90(Pt 1):210-5. (PMID: 19088291)
J Virol. 2012 Jan;86(2):773-85. (PMID: 22072774)
Antiviral Res. 2013 Oct;100(1):159-89. (PMID: 23906741)
PLoS One. 2015 Apr 23;10(4):e0124966. (PMID: 25905707)
PLoS One. 2011;6(12):e28594. (PMID: 22163042)
PLoS Pathog. 2014 Mar 27;10(3):e1003894. (PMID: 24676359)
J Med Virol. 2008 Aug;80(8):1397-404. (PMID: 18551619)
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E838-47. (PMID: 23401522)
PLoS One. 2008 Apr 30;3(4):e2032. (PMID: 18446221)
Cell Rep. 2017 Sep 5;20(10):2396-2407. (PMID: 28877473)
Cytokine Growth Factor Rev. 2014 Oct;25(5):621-8. (PMID: 24894317)
iScience. 2019 Sep 27;19:647-661. (PMID: 31465999)
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1577-82. (PMID: 25605921)
J Infect Dis. 2013 Jun 15;207(12):1909-21. (PMID: 23417661)
J Biol Chem. 2005 Apr 29;280(17):16739-47. (PMID: 15737993)
PLoS Pathog. 2019 Jan 10;15(1):e1007515. (PMID: 30629698)
Trends Immunol. 2017 Feb;38(2):79-93. (PMID: 27887993)
J Virol. 2017 Apr 28;91(10):. (PMID: 28250124)
J Biol Chem. 2016 Jan 8;291(2):582-92. (PMID: 26574543)
Sci Rep. 2016 May 24;6:26637. (PMID: 27217069)
PLoS One. 2014 Nov 12;9(11):e112014. (PMID: 25390891)
Substance Nomenclature:
0 (Cytokines)
0 (Interferon Type I)
0 (Ubiquitins)
60267-61-0 (ISG15 protein, human)
EC 2.7.7.6 (DNA-Directed RNA Polymerases)
EC 3.4.- (Peptide Hydrolases)
Entry Date(s):
Date Created: 20200915 Date Completed: 20201028 Latest Revision: 20201028
Update Code:
20240104
PubMed Central ID:
PMC7518590
DOI:
10.1371/journal.pntd.0008610
PMID:
32931521
Czasopismo naukowe
Crimean-Congo Hemorrhagic Fever virus (CCHFV; family Nairoviridae) is an extremely pathogenic member of the Bunyavirales order. Previous studies have shown that the N-terminal domain of the CCHFV polymerase (L) contains an ovarian tumor-type protease (OTU) domain with the capability to remove both ubiquitin and ISG15 molecules from proteins. The approximately 200 amino acids-long OTU domain, if ectopically expressed, can interfere with both the induction of antiviral type I interferons (IFN) as well as the IFN-stimulated signaling. A OTU protease mutant (C40A), by contrast, was inactive in that respect. However, the effect of the OTU protease activity in the context of the full-length L protein (approximately 4000 amino acids) is only poorly characterized, and recombinant CCHFV with the C40A mutation could not be rescued. Here, we employed transcriptionally active virus-like particles (tc-VLPs) to investigate the interaction between the L-embedded OTU protease and the IFN system. Our data show a cis requirement of the OTU protease for optimal CCHFV polymerase activity in human HuH-7 cells. The L-embedded OTU did not influence IFN signaling, the sensitivity to IFN, or IFN induction. Moreover, the attenuation of OTU C40A-mutated L could not be relieved by inactivating the IFN response, but after overexpression of conjugation-competent ISG15 the polymerase activity recovered to wild-type levels. Consequently, ISG15 was used to produce OTU-deficient tc-VLPs, a potential vaccine candidate. Our data thus indicate that in the context of full-length L the OTU domain is important for the regulation of CCHFV polymerase by ISG15.
Competing Interests: The authors have declared that no competing interests exist.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies